Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

The Associated Press September 22, 2011, 5:46PM ET

FDA halts Immunomedics trial after incorrect dose

Immunomedics said Thursday federal health regulators have halted a study of the company's experimental pancreatic cancer drug after one patient received an incorrect dose of the medication.

The company said the Food and Drug Administration placed a clinical hold on the study after investigators discovered the patient received a higher-than-prescribed dose. The patient "remains on study with no critical toxicity," the company said in a statement.

The company is working with the FDA to file the necessary paperwork to resume the trial.

Company shares fell 25 cents, or 6.7 percent, to close at $3.50.


BW Mall - Sponsored Links

Buy a link now!